The immune response to severe bacterial infections: consequences for therapy

References

• Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med.29(7), 1303–1310 (2001).
   PubMed Web of Science ®Google Scholar
• Bosmann M, Russkamp NF, Patel VR, Zetoune FS, Sarma JV, Ward PA. The outcome of polymicrobial sepsis is independent of T and B cells. Shock36(4), 396–401 (2011).
   PubMedGoogle Scholar
• Beutler BA. TLRs and innate immunity. Blood113(7), 1399–1407 (2009).
   PubMed Web of Science ®Google Scholar
• Weighardt H, Holzmann B. Role of Toll-like receptor response for sepsis pathogenesis. Immunobiology212(9–10), 715–722 (2008).
   Google Scholar
• Jin X, Lin Z, Xie X. The delayed response of Toll-like receptors may relate to Pseudomonas aeruginosa keratitis exacerbating rapidly at the early stages of infection. Eur. J. Clin. Microbiol. Infect. Dis.29(2), 231–238 (2010).
   PubMed Web of Science ®Google Scholar
• Spiller S, Elson G, Ferstl R et al. TLR-induced IFN-γ production increases TLR2 sensitivity and drives Gram-negative sepsis in mice. J. Exp. Med.205(8), 1747–1754 (2008).
   PubMed Web of Science ®Google Scholar
• Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat. Rev. Immunol.10(7), 479–490.
   PubMedGoogle Scholar
• Smith RP, Baltch AL, Ritz WJ, Michelsen PB, Bopp LH. IFN-γ enhances killing of methicillin-resistant Staphylococcus aureus by human monocytes more effectively that GM-CSF in the presence of daptomycin and other antibiotics. Cytokine51(3), 274–277 (2010).
   PubMedGoogle Scholar
• Lordoño D, Marques A, Hornung RL, Cadavid D. IL-10 helps control pathogen load during high-level bacteremia. J. Immunol.181(3), 2076–2083 (2008).
   PubMedGoogle Scholar
• van der Poll T, van Zoelen MAD, Wiersinga WJ. Regulation of pro- and anti-inflammatory host responses. Contrib. Microbiol.17, 125–136 (2011).
   PubMedGoogle Scholar
• Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu. Rev. Immunol.27, 229–265 (2009).
   PubMed Web of Science ®Google Scholar
• Porfyridis I, Plachouras D, Karagianni V et al. Diagnostic value of triggering receptor expressed on myeloid cells-1 and C-reactive protein for patients with lung infiltrates: an observational study. BMC Infect. Dis.10, 286 (2010).
   PubMedGoogle Scholar
• Ford JW, McVicar DW. TREM and TREM-like receptors in inflammation and disease. Curr. Opin. Immunol.21(1), 38–46 (2009).
   PubMed Web of Science ®Google Scholar
• Gibot S, Kolopp-Sarda MN, Béné MC et al. A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis. J. Exp. Med.200(11), 1419–1426 (2004).
   PubMed Web of Science ®Google Scholar
• Ablasser A, Bauernfeind F, Hartmann G, Latz E, Fitzgerald KA, Hornung V. RIG-I dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat. Immunol.10(10), 1065–1073 (2009).
   PubMed Web of Science ®Google Scholar
• Sharma S, De Oliveira RB, Kalantari P et al. Innate immune recognition of an AT-rich stem-loop DNA motif in the Plasmodium falciparum genome. Immunity35(2), 194–207 (2011).
   PubMed Web of Science ®Google Scholar
• Kinjo Y, Illarionov P, Vela JL et al. Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteria. Nat. Immunol.12(10), 966–975 (2011).
   PubMedGoogle Scholar
• Giamarellos-Bourboulis EJ. What is the pathophysiology of the septic host upon admission? Int. J. Antimicrob. Agents36(Suppl. 2), S2–S5 (2010).
   PubMed Web of Science ®Google Scholar
• Uhlig HH, McKenzie BS, Hue S et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity25(2), 309–318 (2006).
   PubMed Web of Science ®Google Scholar
• O’Dwyer MJ, Mankan AK, White M et al. The human response to infection is associated with distinct patterns of interleukin 23 and interleukin 27 expression. Intensive Care Med.34(4), 683–691 (2008).
   PubMedGoogle Scholar
• Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur. J. Immunol.40(7), 1830–1835 (2010).
   PubMed Web of Science ®Google Scholar
• Vincent JL, Sun Q, Dubois MJ. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin. Infect. Dis.34, 1084–1093 (2003).
   Web of Science ®Google Scholar
• Wang H, Ma S. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. Am. J. Emerg. Med.26(6), 711–715 (2008).
   PubMed Web of Science ®Google Scholar
• Bozza FA, Salluh JI, Japiassu AM et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit. Care11(2), R49 (2007).
   PubMed Web of Science ®Google Scholar
• Phua J, Koay ES, Lee KH. Lactate, procalcitonin, and amino-terminal pro-B-type natriuretic peptide versus cytokine measurements and clinical severity scores for prognostication in septic shock. Shock29(3), 328–333 (2008).
   PubMed Web of Science ®Google Scholar
• Emonts M, Sweep FC, Grebenchtchikov N et al. Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis. Crit. Care Med.44(10), 1321–1328 (2007).
   Google Scholar
• Lukaszewicz AC, Grienay M, Resche-Rigon M et al. Monocytic HLA-DR expression in intensive care patients: interest for prognosis and secondary infection prediction. Crit. Care Med.37(10), 2746–2752 (2009).
   PubMed Web of Science ®Google Scholar
• Sinistro A, Almerighi C, Ciaprini C et al. Downregulation of CD40 ligand response in monocytes form sepsis patients. Clin. Vacc. Immunol.15(12), 1851–1858 (2008).
   PubMedGoogle Scholar
• Giamarellos-Bourboulis EJ, van de Veerdonk FL, Mouktaroudi M et al. Inhibition of caspase-1 activation in Gram-negative sepsis and experimental endotoxemia. Crit. Care15(1), R27 (2011).
   PubMed Web of Science ®Google Scholar
• O’Dwyer MJ, Mankan AK, Stordeur P et al. The occurrence of severe sepsis and septic shock are related to distinct patterns of cytokine gene expression. Shock26(6), 544–550 (2006).
   PubMed Web of Science ®Google Scholar
• Dimopoulou I, Pelekanou A, Mavrou I et al. Early serum levels of soluble triggering receptor expressed on myeloid cells-1 in septic patients: Correlation with monocyte gene expression. J. Crit. Care doi:10.1016/j.jcrc.2011.06.013 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Muenzer JT, Davis CG, Chang K et al. Characterization and modulation of the immunosuppressive phase of sepsis. Infect. Immun.78(4), 1582–1592 (2010).
   PubMedGoogle Scholar
• Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J. Infect. Dis.181(1), 176–180 (2000).
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Zakynthinos S, Baziaka F et al. Soluble triggering receptor expressed on myeloid cells 1 as an anti-inflammatory mediator in sepsis. Intensive Care Med.32(2), 237–243 (2006).
   PubMed Web of Science ®Google Scholar
• Kessel A, Bamberger E, Masalha M, Toubi E. The role of T regulatory cells in sepsis. J. Autoimmun.32(3–4), 211–215 (2009).
   PubMed Web of Science ®Google Scholar
• Venet F, Pachot A, Debard AL et al. Human CD4+CD25+ regulatory T lymphocytes inhibit lipopolysaccharide-induced monocyte survival through a Fas/Fas ligand-dependent mechanism. J. Immunol.177(9), 6540–6547 (2006).
   PubMedGoogle Scholar
• Venet F, Chung CS, Kherouf H et al. Increased circulating regulatory T cells (CD4+CD25+CD127-) contribute to lymphocyte anergy in septic shock patients. Intensive Care Med.35(4), 678–686 (2009).
   PubMed Web of Science ®Google Scholar
• Hotchkiss RS, Tinsley K W, Swanson PE et al. Sepsis- induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J. Immunol.166(11), 6952–6953 (2001).
   PubMed Web of Science ®Google Scholar
• Wesche DE, Lomas-Neira JL, Perl M, Chung CS, Ayala A. Leucocyte apoptosis and its significance in sepsis and shock. J. Leukoc. Biol.78(2), 325–337 (2005).
   PubMed Web of Science ®Google Scholar
• Unsinger J, McDonough JS, Shultz LD, Ferguson TA, Hotchkiss RS. Sepsis-induced human lymphocyte apoptosis and cytokine production in “humanized” mice. J. Leukoc. Biol.86(2), 219–227 (2009).
   PubMed Web of Science ®Google Scholar
• Martignoni A, Tschöp J, Goetzman HS et al. CD4-expressing cells are early mediators of the innate immune system during sepsis. Shock29(5), 591–597 (2008).
   PubMedGoogle Scholar
• Chang KC, Unsinger J, Davis CG et al. Multiple triggers of cell death in sepsis: death receptor and mitochondrial-mediated apoptosis. FASEB J.21(3), 708–719 (2007).
   PubMed Web of Science ®Google Scholar
• Schmidt MV, Paulus P, Kuhn AM et al. Peroxisome proliferator-activated receptor γ-induced T cell apoptosis reduces survival during polymicrobial sepsis. Am. J. Resp. Crit. Care Med.184(1), 64–74 (2011).
   PubMedGoogle Scholar
• Vaki I, Kranidioti H, Karagianni V et al. An early circulating factor in severe sepsis modulates apoptosis of monocytes and lymphocytes. J. Leukoc Biol.89(3), 343–349 (2011).
   PubMedGoogle Scholar
• Rosas-Ballina M, Ochani M, Parrish WR et al. Splenic nerve is required for cholinergic anti-inflammatory pathway control of TNF in endotoxemia. Proc. Natl Acad. Sci. USA105(31), 11008–11013 (2008).
   PubMed Web of Science ®Google Scholar
• Su X, Matthay MA, Malik AB. Requisite role of the cholinergic α7 nicotinic acetylcholine receptor pathway in suppressing Gram-negative sepsis-induced acute lung inflammatory injury. J. Immunol.184(1), 401–410 (2009).
   PubMedGoogle Scholar
• Etogo AO, Nunez J, Lin CY, Toliver-Kinsky TE, Sherwood ER. NK but not CD1-restricted NKT cells facilitate systemic inflammation during polymicrobial intra-abdominal sepsis. J. Immunol.180(9), 6334–6345 (2008).
   PubMed Web of Science ®Google Scholar
• Hu CK, Venet F, Heffernan DS, Wang YL et al. The role of hepatic invariant NKT cells in systemic/local inflammation and mortality during polymicrobial septic shock. J. Immunol.182(4), 2467–2475 (2009).
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim SJ, Lee IM et al. Bacterial endotoxin induces the release of high mobility group box a via the IFN-β signaling pathway. J. Immunol.182(4), 2458–2466 (2009).
   PubMedGoogle Scholar
• Gibot S, Massin F, Cravoisy A et al. High mobility group box 1 protein plasma concentrations during septic shock. Intensive Care Med.33(8), 1347–1353 (2007).
   PubMed Web of Science ®Google Scholar
• Silva E, Arcaroli J, He Q et al. HMGB1 and LPS induce distinct patterns of gene expression and activation in neutrophils from patients with sepsis-induced acute lung injury. Intensive Care Med.33(10), 1829–1839 (2007).
   PubMed Web of Science ®Google Scholar
• Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat. Immunol.8(10), 776–786 (2008).
   Google Scholar
• Zhang Q, Raoof M, Chen Y et al. Circulating mitochondrial DAMPs cause inflammation response to injury. Nature464(7285), 104–108 (2010).
   PubMed Web of Science ®Google Scholar
• Pelekanou A, Tsangaris I, Kotsaki A et al. Decrease of CD4-lymphocytes and apoptosis of CD14-monocytes are characteristic alterations in sepsis caused by ventilator-associated pneumonia: results from an observational study. Crit. Care13(6), R172 (2009).
   PubMedGoogle Scholar
• Gogos C, Kotsaki A, Pelekanou A et al. Early alterations of the innate and adaptive immune statuses in sepsis according to the type of underlying infection. Crit. Care14(3), R96 (2010).
   PubMedGoogle Scholar
• van Zoelen MAD, Laterre PF, van Veen SQ et al. Systemic and local high mobility group box 1 concentrations during severe infections. Crit. Care Med.35(12), 2799–2804 (2007).
   PubMed Web of Science ®Google Scholar
• Kasten KR, Prakash PS, Unsinger J et al. Interleukin-7 (IL-7) treatment accelerates neutrophils recruitment through γδ T-cell IL-17 production in a murine model of sepsis. Infect. Immun.78(11), 4714–4722 (2010).
   PubMedGoogle Scholar
• Flohé SB, Agrawal H, Flohé S, Rani M, Bangen JM, Schade FU. Diversity of interferon γ and granulocyte–macrophage-colony stimulating factor in restoring immune dysfunction of dendritic cells and macrophages during polymicrobial sepsis. Mol. Med.14(5–6), 247–256 (2008).
   PubMedGoogle Scholar
• Bo L, Wang F, Zhu J, Li J, Deng X. Granulocyte-colony stimulating factor (G-CSF) and granulocyte–macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit. Care15(1), R58 (2011).
   PubMed Web of Science ®Google Scholar
• Stephens DP, Thomas JH, Dip G et al. Randomized, double-blind, placebo-controlled trials of ganulocyte colony stimulating factor in patients with septic shock. Crit. Care Med.36(2), 448–454 (2008).
   PubMedGoogle Scholar
• Cheng AC, Limmathurotsakul D, Chierakul W et al. A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand. Clin. Infect. Dis.45(3), 308–314 (2007).
   PubMed Web of Science ®Google Scholar
• Rosenbloom AJ, Linden PK, Dorrance A, Penkosky N, Cohen-Melamed MH, Rinsky MR. Effect of granulocyte-monocyte colony-stimulating factor therapy on leukocyte function and clearance of serious infection in non-neutropenic patients. Chest127(6), 2139–2150 (2005).
   PubMed Web of Science ®Google Scholar
• Schefold JC, Zeden JP, Pschowski R et al. Treatment with granulocyte–macrophage colony-stimulating factor is associated with reduced indoleamine 2,3-dioxygenase activity and kynurenine pathway catabolites in patients with severe sepsis and septic shock. Scand. J. Infect. Dis.42(3), 164–171 (2010).
   PubMed Web of Science ®Google Scholar
• Hall MW, Knatz NL, Vetterly C et al. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med.37(3), 525–532 (2011).
   PubMed Web of Science ®Google Scholar
• Döcke WD, Randow F, Syrbe U et al. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat. Med.3(6), 678–681 (1997).
   PubMed Web of Science ®Google Scholar
• Cruz DN, Perazella MA, Bellomo R et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit. Care11(2), R47 (2007).
   PubMed Web of Science ®Google Scholar
• Shimizu T, Hanasawa K, Sato K et al. Direct hemoperfusion with polymyxin-B-immobilized fiber columns improves septic hypotension and reduces inflammatory mediators in septic patients with colorectal perforation. Langenbecks Arch. Surg.394(2), 303–311 (2009).
   PubMedGoogle Scholar
• Kushi H, Miki T, Okamaoto K, Nakahara J, Saito T, Tanjoh K. Early hemoperfusion with an immobilized polymyxin B fiber column eliminates humoral mediators and improves pulmonary oxygenation. Crit. Care9(6), R653–R661 (2005).
   PubMed Web of Science ®Google Scholar
• Ono S, Tsujimoto H, Matsumoto A, Ikuta S, Kinoshita M, Mochizuki H. Modulation of human leukocyte antigen-DR on monocytes and CD16 on granulocytes in patients with septic shock using hemoperfusion with polymyxin B-immobilized fiber. Am. J. Surg.188(2), 150–156 (2004).
   PubMedGoogle Scholar
• Vincent JL, Laterre PF, Cohen J et al. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock23(5), 400–405 (2005).
   PubMed Web of Science ®Google Scholar
• Cruz DN, Antonelli M, Fumagalli R et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA301(23), 2445–2452 (2009).
   PubMed Web of Science ®Google Scholar
• Mitaka C, Tsuchida N, Kawada K, Nakajima Y, Imai T, Sasaki S. A longer duration of polymyxin B-immobilized fiber column hemoperfusion improves pulmonary oxygenation in patients with septic shock. Shock32(5), 478–483 (2009).
   PubMed Web of Science ®Google Scholar
• Mullarkey M, Rose JR, Bristol J et al. Inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J. Pharmacol. Exp. Ther.304(3), 1093–1102 (2003).
   PubMed Web of Science ®Google Scholar
• Tidswell M, Tillis W, LaRosa SP et al. Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis. Crit. Care Med.38(1), 72–83 (2010).
   PubMed Web of Science ®Google Scholar
• Kalil AC, Larosa SP, Gogate J, Lynn M, Opal SM. Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsis. Shock36(4), 327–331 (2011).
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int. J. Antimicrob. Agents31(1), 12–20 (2008).
   PubMed Web of Science ®Google Scholar
• García Vázquez E, Mensa J, Martínez JA et al. Lower mortality among patients with community-acquired pneumonia treated with a aacrolide plus a beta-lactam agent versus a beta-lactam agent alone. Eur. J. Clin. Microbiol. Infect. Dis.24, 190–195 (2005).
   PubMed Web of Science ®Google Scholar
• Martínez , JA, Horcajada JP, Almela M et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin. Infect. Dis.36, 389–395 (2003).
   PubMed Web of Science ®Google Scholar
• Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur. Respir. J.33(1), 153–159 (2009).
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Pechère JC, Routsi C et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin. Infect. Dis.46(8), 1157–1164 (2008).
   PubMed Web of Science ®Google Scholar
• Chastre J, Wolff W, Fagon JY et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults. JAMA290(19), 2588–2598 (2003).
   PubMed Web of Science ®Google Scholar
• Thomsen RW, Riis A, Kornum JB, Christensen S, Johnsen SP, Sørensen HT. Preadmission use of statins and outcomes after hospitalization with pneumonia. Arch. Intern. Med.168(19), 2081–2087 (2008).
   PubMed Web of Science ®Google Scholar
• O’ Neal HR Jr, Koyama T, Koehler EAS et al. Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acure respiratory distress syndrome. Crti. Care Med.39(6), 1343–1350 (2011).
   PubMedGoogle Scholar
• Novack V, Eisinger M, Frenkel A et al. The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trial. Intensive Care Med.35(7), 1255–1260 (2009).
   PubMed Web of Science ®Google Scholar
• Wesche-Soldato DE, Swan RZ, Chung CS, Ayala A. The apoptotic pathway as a therapeutic target in sepsis. Curr. Drug Targets8(4), 493–500 (2007).
   PubMed Web of Science ®Google Scholar
• Yang H, Tracey KJ. Targeting HMGB1 in inflammation. Biochim. Biophys. Acta1799(1–2), 149–156 (2010).
   PubMed Web of Science ®Google Scholar
• Dellinger RP, Levy MM, Carlet JM et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit. Care Med.36(1), 296–327 (2008).
   PubMed Web of Science ®Google Scholar